Photodynamic therapy using an anti-EGF receptor antibody complexed with verteporfin nanoparticles: A proof of concept study

Cancer Biotherapy and Radiopharmaceuticals

Volumn 26, Issue 6, 2011, Pages 697-704

  Kameyama, Noriaki ^a,b   Matsuda, Sachiko ^b   Itano, Osamu ^b   Ito, Arisa ^b   Konno, Tomohiro ^c   Arai, Tsunenori ^b   Ishihara, Kazuhiko ^c   Ueda, Masakazu ^b   Kitagawa, Yuko ^b  

^a International Goodwill Hospital   (Japan)

^b KEIO UNIVERSITY   (Japan)

^c UNIVERSITY OF TOKYO   (Japan)

Author keywords

antibody complex; cancer; endothelial growth factor receptor; photodynamic therapy; verteporfin

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; UNCLASSIFIED DRUG; VERTEPORFIN; VERTEPORFIN POLY[2 METHACRYLOYLOXYETHYL PHOSPHORYLCHOLINE CO N BUTYL METHACRYLATE CO P NITROPHENYLCARBONYLOXYETHYL METHACRYLATE ANTIBODY COMPLEX; VERTEPORIN PLUS POLY[2 METHACRYLOYLOXYETHYL PHOSPHORYLCHOLINE CO N BUTYLMETHACRYLATE CO P NITROPHENYLCARBONYLOXYETHYL METHACRYLATE];

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; DRUG CONJUGATION; DRUG STRUCTURE; DRUG TISSUE LEVEL; DRUG UPTAKE; FEMALE; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIATION DOSE; TUMOR VOLUME;

ANIMALS; ANTIBODIES, MONOCLONAL; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; FEMALE; LUNG NEOPLASMS; MICE; MICE, INBRED BALB C; NANOPARTICLES; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; POLYMYXIN B; PORPHYRINS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SURVIVAL RATE;

EID: 83455262972     PISSN: 10849785     EISSN: 15578852     Source Type: Journal    
DOI: 10.1089/cbr.2011.1027     Document Type: Article

References (39)

1. Harrod-Kim P. Tumor ablation with photodynamic therapy: Introduction to mechanism and clinical applications. J Vasc Interv Radiol 2006;17:1441.
2. Schmidt-Erfurth U, Hasan T. Mechanisms of action of pho-todynamic therapy with verteporfin for the treatment of age-related macular degeneration. Surv Ophthalmol 2000;45:195.
3. Arevalo JF, Espinoza JV. Single-session combined photo-dynamic therapy with verteporfin and intravitreal anti-vascular endothelial growth factor therapy for chronic central serous chorioretinopathy: A pilot study at 12-month follow-up. Graefes Arch Clin Exp Ophthalmol Mar 30, 2011 DOI: 10.1007/s00417-011-1651-7. Epub ahead of print.
4. Blasi MA, Tiberti AC, Scupola A, et al. Photodynamic therapy with verteporfin for symptomatic circumscribed choroidal hemangioma: Five-year outcomes. Ophthalmology 2010;117:1630.
5. Boixadera A, Garcia-Arumi J, Martinez-Castillo V, et al. Prospective clinical trial evaluating the efficacy of photo-dynamic therapy for symptomatic circumscribed choroidal hemangioma. Ophthalmology 2009;116:100.e1.
6. Chan WM, Lim TH, Pece A, et al. Verteporfin PDT for non-standard indications-A review of current literature. Graefes Arch Clin Exp Ophthalmol 2010;248:613.
7. Eskelin S, Tommila P, Palosaari T, et al. Photodynamic therapy with verteporfin to induce regression of aggressive retinal astrocytomas. Acta Ophthalmol 2008;86:794.
8. Lo Giudice G, Gismondi M, De Belvis V, et al. Single-session photodynamic therapy combined with intravitreal bev-acizumab for retinal angiomatous proliferation. Retina 2009; 29:949.
9. Hsu MJ, Juliano RL. Interactions of liposomes with the reticuloendothelial system. II: Nonspecific and receptor-mediated uptake of liposomes by mouse peritoneal macro-phages. Biochim Biophys Acta 1982;720:411.
10. Jori G, Reddi E, Cozzani I, et al. Controlled targeting of different subcellular sites by porphyrins in tumour-bearing mice. Br J Cancer 1986;53:615.
11. Soncin M, Polo L, Reddi E, et al. Effect of the delivery system on the biodistribution of Ge(IV) octabutoxy-phthalocyanines in tumour-bearing mice. Cancer Lett 1995;89:101.
12. Gijsens A, Missiaen L, Merlevede W, et al. Epidermal growth factor-mediated targeting of chlorin e6 selectively potentiates its photodynamic activity. Cancer Res 2000; 60:2197.
13. Brasseur N, Ouellet R, La Madeleine C, et al. Water-soluble aluminium phthalocyanine-polymer conjugates for PDT: Photodynamic activities and pharmacokinetics in tumour-bearing mice. Br J Cancer 1999;80:1533.
14. Hamblin MR, Miller JL, Rizvi I, et al. Pegylation of a chlorin(e6) polymer conjugate increases tumor targeting of photosensitizer. Cancer Res 2001;61:7155.
15. Reuther T, Kubler AC, Zillmann U, et al. Comparison of the in vivo efficiency of photofrin II-, mTHPC-, mTHPC-PEG-and mTHPCnPEG-mediated PDT in a human xenografted head and neck carcinoma. Lasers Surg Med 2001;29:314.
16. Ris HB, Im Hof V, Stewart CM, et al. Endobronchial photodynamic therapy: Comparison of mTHPC and polyethylene glycol-derived mTHPC on human tumor xeno-grafts and tumor-free bronchi of minipigs. Lasers Surg Med 1998;23:25.
17. Rovers JP, Saarnak AE, de Jode M, et al. Biodistribution and bioactivity of tetra-pegylated meta-tetra(hydroxyphenyl)chlorin compared to native meta-tetra(hydroxyphenyl)chlorin in a rat liver tumor model. Photochem Photobiol 2000;71:211.
18. Shiah JG, Sun Y, Peterson CM, et al. Antitumor activity of N-(2-hydroxypropyl) methacrylamide copolymer-Mesochlorine e6 and adriamycin conjugates in combination treatments. Clin Cancer Res 2000;6:1008.
19. Shiah JJ, Sun Y, Peterson CM, et al. Biodistribution of free and N-(2-hydroxypropyl)methacrylamide copolymer-bound mesochlorin e(6) and adriamycin in nude mice bearing human ovarian carcinoma OVCAR-3 xenografts. J Control Release 1999;61:145.
20. Westerman P, Glanzmann T, Andrejevic S, et al. Long circulating half-life and high tumor selectivity of the photo-sensitizer meta- tetrahydroxyphenylchlorin conjugated to polyethylene glycol in nude mice grafted with a human colon carcinoma. Int J Cancer 1998;76:842.
21. Carcenac M, Dorvillius M, Garambois V, et al. Internalisa-tion enhances photo-induced cytotoxicity of monoclonal antibody-phthalocyanine conjugates. Br J Cancer 2001; 85:1787.
22. Mew D, Wat CK, Towers GH, et al. Photoimmunotherapy: Treatment of animal tumors with tumor-specific monoclonal antibody-hematoporphyrin conjugates. J Immunol 1983; 130:1473.
23. Pelegrin A, Folli S, Buchegger F, et al. Antibody-fluorescein conjugates for photoimmunodiagnosis of human colon carcinoma in nude mice. Cancer 1991;67:2529.
24. Soukos NS, Hamblin MR, Keel S, et al. Epidermal growth factor receptor-targeted immunophotodiagnosis and photo-immunotherapy of oral precancer in vivo. Cancer Res 2001; 61:4490.
25. Vrouenraets MB, Visser GW, Loup C, et al. Targeting of a hydrophilic photosensitizer by use of internalizing monoclonal antibodies: A new possibility for use in photodynamic therapy. Int J Cancer 2000;88:108.
26. Chiba N, Ueda M, Shimada T, et al. Novel immunosup-pressant agents targeting activated lymphocytes by bio-compatible MPC polymer conjugated with interleukin-2. Eur Surg Res 2007;39:103.
27. Ishihara K, Nomura H, Mihara T, et al. Why do phospho-lipid polymers reduce protein adsorption? J Biomed Mater Res 1998;39:323.
28. Ishihara K, Oshida H, Endo Y, et al. Hemocompatibility of human whole blood on polymers with a phospholipid polar group and its mechanism. J Biomed Mater Res 1992; 26:1543.
29. Konno T, Kurita K, Iwasaki Y, et al. Preparation of nano-particles composed with bioinspired 2-methacryloylox-yethyl phosphorylcholine polymer. Biomaterials 2001; 22:1883.
30. Ozawa S, Ueda M, Ando N, et al. High incidence of EGF receptor hyperproduction in esophageal squamous-cell carcinomas. Int J Cancer 1987;39:333.
31. Arteaga CL. Overview of epidermal growth factor receptor biology and its role as a therapeutic target in human neo-plasia. Semin Oncol 2002;29(5Suppl14):3.
32. Baselga J. Why the epidermal growth factor receptor? The rationale for cancer therapy. Oncologist 2002;7(Suppl 4):2.
33. Mendelsohn J. Targeting the epidermal growth factor receptor for cancer therapy. J Clin Oncol 2002;20(18Suppl):1S.
34. Hirota N, Ueda M, Ozawa S, et al. Suppression of an epidermal growth factor receptor-hyperproducing tumor by an immunotoxin conjugate of gelonin and a monoclonal anti-epidermal growth factor receptor antibody. Cancer Res 1989;49(24 Pt 1):7106.
35. Konno T, Watanabe J, Ishihara K. Conjugation of enzymes on polymer nanoparticles covered with phosphorylcholine groups. Biomacromolecules 2004;5:342.
36. Miyata R, Ueda M, Jinno H, et al. Selective targeting by preS1 domain of hepatitis B surface antigen conjugated with phosphorylcholine-based amphiphilic block copolymer micelles as a biocompatible, drug delivery carrier for treatment of human hepatocelluar carcinoma with paclitaxel. Int J Cancer 2009;124:2460.
37. Sibata CH, Colussi VC, Oleinick NL, et al. Photodynamic therapy in oncology. Expert Opin Pharmacother 2001;2:917.
38. Matsumura Y, Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: Mechanism of tu-moritropic accumulation of proteins and the antitumor agent smancs. Cancer Res 1986;46(12 Pt 1):6387.
39. Ideta R, Tasaka F, Jang WD, et al. Nanotechnology-based photodynamic therapy for neovascular disease using a su-pramolecular nanocarrier loaded with a dendritic photo-sensitizer. Nano Lett 2005;5:2426.